INDAPTUS THERAPEUTICS INC (INDP)

US45339J1051 - Common Stock

0.8891  -0.05 (-5.21%)

After market: 0.91 +0.02 (+2.35%)

News Image
a month ago - Indaptus Therapeutics

Indaptus Therapeutics, Inc. Announces $2.135 Million Registered Direct Offering and Concurrent Private Placement

NEW YORK, Nov. 22, 2024 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus”), a clinical stage biotechnology company dedicated to...

News Image
a month ago - Indaptus Therapeutics

Indaptus Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

NEW YORK, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”), a clinical stage biotechnology...

News Image
a month ago - Indaptus Therapeutics

Indaptus Therapeutics’ Pioneering Research on Novel Immunotherapy Approach Published in Peer-Reviewed Frontiers in Immunology

Preclinical data demonstrates Decoy platform single agent anti-tumor activity and combination-mediated tumor eradication with NSAID, anti-PD1 checkpoint...

News Image
2 months ago - Indaptus Therapeutics

Indaptus Therapeutics to Present at Two Upcoming Investor Conferences

NEW YORK, Oct. 23, 2024 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) announced today that Jeffrey A. Meckler, Chief Executive Officer,...

News Image
4 months ago - Indaptus Therapeutics

Indaptus Therapeutics Reports Encouraging New Safety Data for Decoy20 Clinical Program; Company Expands Enrollment of Patients on Weekly Dosing at Two Different Doses

NEW YORK, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”), a clinical stage biotechnology...

News Image
4 months ago - InvestorPlace

INDP Stock Earnings: Indaptus Therapeutics Beats EPS for Q2 2024

INDP stock results show that Indaptus Therapeutics beat analyst estimates for earnings per share the second quarter of 2024.

News Image
4 months ago - BusinessInsider

INDP Stock Earnings: Indaptus Therapeutics Beats EPS for Q2 2024

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Indaptus Therapeutics (NASDAQ:INDP) just reported results for the second quarte...

News Image
4 months ago - Indaptus Therapeutics

Indaptus Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update

NEW YORK, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”), a clinical stage biotechnology...

News Image
7 months ago - Indaptus Therapeutics

Indaptus Therapeutics to Present New Positive Data on Decoy20 at Next-Gen Immuno-Oncology Conference

NEW YORK, June 04, 2024 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc, (Nasdaq: INDP), a clinical stage biotechnology company dedicated to pioneering...

News Image
8 months ago - InvestorPlace

INDP Stock Earnings: Indaptus Therapeutics Misses EPS for Q1 2024

INDP stock results show that Indaptus Therapeutics missed analyst estimates for earnings per share the first quarter of 2024.

News Image
8 months ago - BusinessInsider

INDP Stock Earnings: Indaptus Therapeutics Misses EPS for Q1 2024

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Indaptus Therapeutics (NASDAQ:INDP) just reported results for the first quarter...

News Image
8 months ago - Indaptus Therapeutics

Indaptus Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update

Company to present poster at American Society of Clinical Oncology (ASCO) Annual Meeting on June 1, 2024 highlighting initial results from its Phase 1...

News Image
9 months ago - Indaptus Therapeutics

Indaptus Therapeutics Presents Positive Mechanism of Action Data at the American Association for Cancer Research Annual Meeting

Results Indicate Decoy Platform Broadly Boosts Immune System's Ability to Fight Tumors Directly and Indirectly...

News Image
9 months ago - Indaptus Therapeutics

Indaptus Therapeutics Previews Positive Mechanism of Action Data to be Presented at the American Association for Cancer Research Annual Meeting

Data demonstrates that Company’s Decoy platform successfully induces or activates multiple immune cell types involved in anti-tumor responses New...

News Image
10 months ago - Indaptus Therapeutics

Indaptus Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update

Announced Positive Results from Second Cohort of Phase 1 Trial of Decoy20 Initiating Multi-Dosing for patients with solid tumors NEW YORK, March 13,...

News Image
10 months ago - Indaptus Therapeutics

Indaptus Therapeutics Announces Positive Results from Second Cohort of Phase 1 Trial; Company Initiates Multi-Dose Cohort

• Positive data following completion of second cohort of Phase 1 trial of Decoy 20 leads independent Safety Review Committee to recommend initiating...

News Image
11 months ago - Indaptus Therapeutics

Indaptus Therapeutics Expands Digital Presence with Launch of Social Media Channels

NEW YORK, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP), a clinical stage biotechnology company dedicated to pioneering...

News Image
a year ago - Indaptus Therapeutics

European Patent Office Approves Key Patent for Indaptus Therapeutics’ Platform Technology

Patent will provide additional protection covering a composition targeting any viral infection, including hepatitis B, HIV, and influenza...

News Image
a year ago - Indaptus Therapeutics

Indaptus Therapeutics to Present Positive Pharmacodynamic (PD) Immune and Pharmacokinetic (PK) Results with Patients from First Cohort of Ongoing Phase 1 Study of Decoy20 at Cancer Immunotherapy Meeting

Poster to be presented at 38th Annual Meeting of the Society for Immunotherapy of Cancer on November 4, 2023 NEW YORK, Oct. 31, 2023 (GLOBE NEWSWIRE) --...

News Image
a year ago - Indaptus Therapeutics

Indaptus Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference

NEW YORK, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) announced today that Jeffrey A. Meckler, Chief Executive Officer,...

News Image
a year ago - Indaptus Therapeutics

Indaptus Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update

NEW YORK, Aug. 14, 2023 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”) today announced financial results...

News Image
a year ago - Indaptus Therapeutics

Indaptus Therapeutics Announces Opening of Next Cohort in Single Dose Ranging Study of Decoy20

Cohort 1 patients exhibited a significant immune response consistent with the mechanism of actionSafety Review Committee approved continuation to the next...

News Image
a year ago - Indaptus Therapeutics

Indaptus Therapeutics Appoints Industry Veteran Roger Waltzman, M.D. Chief Medical Officer

NEW YORK, Aug. 07, 2023 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP), a biotechnology company focused on discovering and developing...

News Image
2 years ago - Indaptus Therapeutics

Indaptus Therapeutics to Present at the Jefferies Healthcare Conference 2023

NEW YORK, May 31, 2023 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP), a biotechnology company focused on discovering and developing...

News Image
2 years ago - Indaptus Therapeutics

Indaptus Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update

Enrollment Continues for Phase 1 Clinical Trial of Decoy20 for Treatment of Solid Tumors with First Patient Dosed In March 2023...